Hans-Peter Tony
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Koehm M, Foldenauer A, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). J Clin Med 2022; 11
09.12.2022Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
09.12.2022J Clin Med 2022; 11
Koehm Michaela, Foldenauer Ann C, Rossmanith Tanja, Alten Rieke, Aringer Martin, Backhaus Marina, Burmester Gerd R, Feist Eugen, Kellner Herbert, Krueger Klaus, Müller-Ladner Ulf, Rubbert-Roth Andrea, Tony Hans-Peter, Wassenberg Siegfried, Burkhardt Harald, Behrens Frank
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmanith T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology (Oxford) 2021; 60:5318-5328.
03.01.2021Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
03.01.2021Rheumatology (Oxford) 2021; 60:5318-5328
Behrens Frank, Wassenberg Siegfried, Tony Hans-Peter, Rubbert-Roth Andrea, Müller-Ladner Ulf, Lehn Annette, Krueger Klaus, Kellner Herbert, Herrmann Eva, Feist Eugen, Burmester Gerd R, Backhaus Marina, Aringer Martin, Alten Rieke, Rossmanith Tanja, Koehm Michaela, Burkhardt Harald
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin Exp Rheumatol 2019; 37:937-945.
16.04.2019Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
16.04.2019Clin Exp Rheumatol 2019; 37:937-945
Dörner Thomas, Peters Marvin A, Schwenke Holger, Rubbert-Roth Andrea, Krüger Klaus, Kurthen Reiner, Kellner Herbert, Kästner Peter, Engel Andreas, Schmalzing Marc, Iking-Konert Christof, Burmester Gerd-Rüdiger, Schulze-Koops Hendrik, Tony Hans-Peter